Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vancomycin

J E Geraci

    Mayo Clinic Proceedings
    |October 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Vancomycin is a key antibiotic for treating serious staphylococcal infections and other gram-positive bacterial infections when other treatments fail. It is generally safe, with neurotoxicity rarely occurring at recommended serum levels.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    In vitro and in vivo studies of streptomycin-resistant, penicillin-susceptible streptococci from patients with infective endocarditis.

    The Journal of infectious diseases·1987
    Same author

    In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis.

    Antimicrobial agents and chemotherapy·1987
    Same author

    Treatment of streptomycin-susceptible enterococcal experimental endocarditis with combinations of penicillin and low- or high-dose streptomycin.

    Antimicrobial agents and chemotherapy·1986
    Same author

    Activity of penicillin combined with an aminoglycoside against group B streptococci in vitro and in experimental endocarditis.

    The Journal of antimicrobial chemotherapy·1986
    Same author

    Antimicrobial therapy of experimental endocarditis caused by nutritionally variant viridans group streptococci.

    Antimicrobial agents and chemotherapy·1986
    Same author

    Treatment of streptococcal infective endocarditis.

    The American journal of medicine·1985
    Same journal

    Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

    Mayo Clinic proceedings·2026
    Same journal

    RAAS Inhibition in the ICU: Stop, Continue, or Restart?

    Mayo Clinic proceedings·2026
    Same journal

    Chronic Kidney Disease-In the Limelight, July 2026.

    Mayo Clinic proceedings·2026
    Same journal

    In Reply: Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

    Mayo Clinic proceedings·2026
    Same journal

    Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

    Mayo Clinic proceedings·2026
    Same journal

    Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.

    Mayo Clinic proceedings·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Clinical Microbiology

    Background:

    • Vancomycin is a critical bactericidal antibiotic for specific clinical infections.
    • It serves as a primary treatment for severe staphylococcal infections when penicillins and cephalosporins are contraindicated or ineffective.
    • Its antibacterial spectrum extends to other gram-positive cocci and bacteria, and gram-negative cocci.

    Purpose of the Study:

    • To outline the therapeutic indications and administration of vancomycin.
    • To detail its use in various serious bacterial infections, including staphylococcal, streptococcal, and enterococcal infections.
    • To describe its safety profile and potential toxicities.

    Main Methods:

    • Intravenous administration is typical, with a standard dose of 1 g every 12 hours for patients with normal renal function.

    Related Experiment Videos

  • Specific indications include severe staphylococcal infections, penicillin-intolerant streptococcal endocarditis, and certain enterococcal infections (often with aminoglycosides).
  • Oral or intravenous vancomycin is used for acute staphylococcal ileocolitis.

    • Main Results:

    • Vancomycin is effective against a range of gram-positive organisms, including resistant strains.
    • It is indicated for serious infections caused by organisms resistant to common agents.
    • Neurotoxicity is the main adverse effect, typically observed when serum levels exceed 30 microgram/ml.

    Conclusions:

    • Vancomycin is a valuable therapeutic option for serious gram-positive bacterial infections, particularly staphylococcal infections.
    • Its use requires careful consideration of specific indications, including patient tolerance and organism resistance.
    • Maintaining serum levels below 30 microgram/ml minimizes the risk of neurotoxicity.